Voyxact Injection
Product Images NDC 59148-400

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Voyxact (NDC 59148-400). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Otsuka America Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Voyxact 01)

A bar chart comparing the estimated percent change with 95% confidence intervals between VOYXACT 400 mg and placebo groups. The VOYXACT bar shows approximately -50% change (n=152), while the placebo bar indicates a 2% change (n=168), with error bars illustrating variability.*

FDA Label Image

Figure 2 (Voyxact 02)

A line graph comparing percent change with 95% confidence intervals over 40 weeks between VOYXACT 400 mg (n=152) and placebo (n=168). The x-axis shows visit weeks from baseline to 40, and the y-axis shows percent change from -60% to 20%. Data points indicate VOYXACT shows a decreasing trend in percent change, while placebo remains relatively stable near 0%.*

FDA Label Image

Image (Voyxact 03)

An instructional illustration showing the components of a subcutaneous injection device for VOYXACT (sibeprenlimab) before use, including the plunger rod, finger flange, viewing window, needle guard, needle, and needle cap. The 'After Use' image shows the device with the needle retracted for safety.*

FDA Label Image

Figure A (Voyxact 04)

An illustration depicting a closed box beside a clock showing a shaded area indicating a wait time of 15 to 30 minutes. The image suggests waiting for 15 to 30 minutes, likely related to preparation or administration timing instructions.*

FDA Label Image

Image (Voyxact 05)

An instructional illustration showing the components included in the VOYXACT subcutaneous injection kit: a prefilled syringe inside a box, alcohol swabs, cotton balls or gauze, adhesive bandages, and a sharps disposal container.*

FDA Label Image

Figure B (Voyxact 06)

An instructional illustration showing a hand holding a syringe labeled for subcutaneous injection, being removed from a segmented tray inside a box or packaging. An upward arrow indicates lifting the syringe out of the tray.*

FDA Label Image

Figure C (Voyxact 07)

An instructional illustration showing a syringe with a viewing window highlighting the expiration date area labeled as 'EXP: YYYY-MMM'. The syringe appears to be designed for subcutaneous injection, likely associated with VOYXACT (sibeprenlimab) 200 mg/mL injection by Otsuka America Pharmaceutical.*

FDA Label Image

Figure D (Voyxact 08)

An instructional illustration showing preferred injection sites for VOYXACT (sibeprenlimab) subcutaneous injection. Areas on the front of the body where self or caregiver injection is allowed are highlighted in orange, including the abdomen and thighs. A blue highlighted area on the back of the upper arm indicates injection sites exclusively for caregiver administration.*

FDA Label Image

Figure E (Voyxact 09)

An instructional illustration showing a person washing their hands under running water from a faucet, with soap bubbles visible on the hands. The image emphasizes hand hygiene.*

FDA Label Image

Figure F (Voyxact 10)

An instructional illustration showing a hand pressing a small rectangular patch onto a flat surface, likely demonstrating application technique for a product delivery or testing method.*

FDA Label Image

Figure G (Voyxact 11)

An instructional illustration showing a hand holding a prefilled syringe labeled VOYXACT (sibeprenlimab) injection, 200 mg/mL. The syringe is positioned for subcutaneous administration; an arrow points left, indicating the direction for removing the syringe cap or needle cover.*

FDA Label Image

Figure H (Voyxact 12)

An instructional illustration showing the proper subcutaneous injection technique for VOYXACT (sibeprenlimab). The syringe is held at a 45-degree angle to the skin, with an arrow indicating the direction of needle insertion into the skin fold on the arm.*

FDA Label Image

Figure I (Voyxact 13)

An instructional illustration depicting a hand holding a VOYXACT injection device, with a close-up inset highlighting the step of preparing or securing the device before subcutaneous administration.*

FDA Label Image

Figure J (Voyxact 14)

An illustration showing a hand holding a subcutaneous injection device, with an arrow pointing upward indicating the removal or pulling off of a protective cap or cover from the injection syringe. This is likely a step in the preparation or administration process for the VOYXACT sibeprenlimab injection.*

FDA Label Image

Figure K (Voyxact 15)

An instructional illustration showing a hand holding a prefilled syringe, positioned for subcutaneous injection with the needle angled upward and ready for administration in a patient's skin. This visual aids proper injection technique for VOYXACT (sibeprenlimab) 200 mg/mL subcutaneous injection.*

FDA Label Image

Figure L (Voyxact 16)

An illustration showing the disposal of a syringe into a sharps container. The syringe appears to be uncapped and angled toward the open top of the container, indicating proper injection disposal protocol.*

FDA Label Image

Principal Display Panel (200 mg/mL Syringe Carton)

Carton packaging label for VOYXACT (sibeprenlimab-szsi) injection, containing one single-dose prefilled syringe. The product strength is 400 mg/2 mL (200 mg/mL) for subcutaneous use. The label displays product information including inactive ingredients, storage instructions, manufacturer and distributor details from Otsuka America Pharmaceutical, Inc., and a QR code for additional information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.